Table 2 Number of infections and antimicrobial prescriptions among SMM individuals and MGUS-free comparators.
From: Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
SMM | MGUS-free comparators | HR (95% CI) | ||
|---|---|---|---|---|
Total, N | 162 | 810 | Time-to-first infection | Recurrent infection |
All infections (ICD-10 codes), N | 181 | 873 | 1.36 (1.07–1.73) | 1.22 (0.97–1.53) |
Other infections, N | 47 | 214 | 1.45 (0.99–2.11) | 1.33 (0.89–2.01) |
Bacterial infections, N | 60 | 333 | 1.13 (0.80–1.59) | 1.07 (0.75–1.51) |
Viral infections, N | 50 | 255 | 1.22 (0.85–1.75) | 1.19 (0.82–1.73) |
Fungal infections, N | 24 | 71 | 1.14 (0.60–2.17) | 1.37 (0.62–3.04) |
All antimicrobials (ATC codes), N | 454 | 2472 | 1.06 (0.87–1.30) | 1.09 (0.91–1.31) |
Antibacterial, N | 413 | 2180 | 1.24 (1.01–1.52) | 1.10 (0.91–1.32) |
Antiviral, N | 13 | 83 | 1.09 (0.54–2.22) | 1.00 (0.48–2.08) |
Antifungal, N | 28 | 209 | 1.07 (0.65–1.76) | 0.91 (0.52–1.60) |
